Evotec SE (NASDAQ:EVO – Get Free Report)’s share price fell 2.7% on Thursday after HC Wainwright lowered their price target on the stock from $11.00 to $8.00. HC Wainwright currently has a buy rating on the stock. Evotec traded as low as $3.21 and last traded at $3.22. 26,393 shares were traded during trading, a decline of 76% from the average session volume of 110,617 shares. The stock had previously closed at $3.31.
A number of other equities research analysts also recently commented on the company. Deutsche Bank Aktiengesellschaft downgraded Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Morgan Stanley cut Evotec from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $15.00 to $6.00 in a report on Monday, July 29th.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC purchased a new stake in shares of Evotec during the 4th quarter valued at about $25,000. Optiver Holding B.V. boosted its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after acquiring an additional 69,936 shares during the period. Mubadala Investment Co PJSC purchased a new position in Evotec in the 4th quarter worth approximately $53,931,000. Cetera Advisors LLC purchased a new position in Evotec in the 1st quarter worth approximately $188,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Evotec in the 2nd quarter worth approximately $87,000. Institutional investors and hedge funds own 5.81% of the company’s stock.
Evotec Price Performance
The stock has a fifty day simple moving average of $4.54 and a two-hundred day simple moving average of $5.91. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.86 and a quick ratio of 1.79.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.